Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD19 CAR-T cells (Xinqiao Hospital)
- Development stage
- Unknown
- Lead developer
- Xinqiao Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
CD19 CAR-T cells (Xinqiao Hospital) is an autologous chimeric antigen receptor (CAR) T-cell therapy developed by Xinqiao Hospital of Chongqing for the treatment of relapsed or refractory CD19-positive B-cell malignancies, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL). The therapy consists of patient-derived T cells transduced with a retroviral vector to express a second-generation CAR comprising an anti-CD19 single-chain variable fragment (scFv) linked to a CD28 costimulatory domain and a CD3-zeta signaling domain. A key feature of this specific program is the investigation of cytokine programming during ex vivo expansion; the "MeCAR" study compares traditional IL-2 expansion with an IL-7/IL-15-based protocol designed to enrich for memory T-cell phenotypes (Tcm/Tn), potentially enhancing in vivo persistence and anti-tumor efficacy.
- Other names
- Anti-CD19:TCRz:CD28 T-cellsIL-7/IL-15 programmed CD19 CAR-T cellsIL-2 programmed CD19 CAR-T cellsIL2 programmed CD19 CAR-T cellsIL 2 programmed CD19 CAR-T cells
02
Targets
Beyond the preview
Go deeper on CD19 CAR-T cells (Xinqiao Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD19 CAR-T cells (Xinqiao Hospital).